Fidaxomicin

Navigation

What is Fidaxomicin?

Fidaxomicin is a narrow-spectrum macrocyclic antibiotic, for treating inpatients with Clostridioides difficile infection (CDI) (1)

What is the significance of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection (CDI)?

Fidaxomicin is costly and is promoted by lobbyists. It's at the top of German guidelines (2), but it lacks solid studies. It's not better than Vancomycin (3, 4).

References

(1) Mikamo et al. 2018 J Infect Chemother 24: 744-52
(2) AWMF Leitlinienregister
(3) AMB 2013, 47, 70
(4) AMB 2011, 45, 30

see…

References (Sources)

Efﬁcacy and safety of ﬁdaxomicin for the treatment of Clostridioides (Clostridium) difﬁcile infection in a randomized, double-blind, comparative phase III study in Japan
Mikamo et al. 2018 J Infect Chemother 24: 744-52

AI Chat

11/5/2026

Chat with our artificial intelligence:

Start chat!

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)